ロード中...
Sym004, a Novel EGFR Antibody Mixture, Can Overcome Acquired Resistance to Cetuximab
The epidermal growth factor receptor (EGFR) is a central regulator of tumor progression in a variety of human cancers. Cetuximab is an anti-EGFR monoclonal antibody that has been approved for head and neck and colorectal cancer treatment, but many patients treated with cetuximab don't respond o...
保存先:
| 主要な著者: | , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Neoplasia Press Inc.
2013
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3819635/ https://ncbi.nlm.nih.gov/pubmed/24204198 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|